2026 oncology meetings
SITC, ESMO, ASCO, AACR and ASH 2026. 285 abstracts found by web research and verified against a source page so far, plus each meeting's journal supplement searched live through Crossref where it is indexed. Titles and metadata only.
SITC
SITC Annual Meeting 2026
4–8 Nov 2026, Phoenix
18
verified abstracts in 1 area
ESMO
ESMO Congress 2026
23–27 Oct 2026, Madrid
146
verified abstracts in 8 areas
ASCO
ASCO Annual Meeting 2026
29 May – 2 Jun 2026, Chicago
13
verified abstracts in 1 area
AACR
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego
10
verified abstracts in 1 area
ASH
ASH Annual Meeting 2026
12–15 Dec 2026, New Orleans
98
verified abstracts in 4 areas
175 of 285 verified abstracts were confirmed on a page we fetched ourselves
Verified abstracts per 2026 meeting, split by how each row was checked. The rest match the text Parallel saved from a page that blocks automated access, mostly ESMO's congress platform.
Found on the cited source pageFound on a second fetched pageMatches only the excerpt saved from a page we could not re-fetch
Rows that failed every check were dropped and are not counted. Source: data/meetings in the project repository, each row linked to its source page.
ESMO Congress 2026
23–27 Oct 2026, Madrid · Annals of Oncology, vol. 37 supplement
The ESMO 2026 abstract supplement was not in Crossref on 11 Nov 2026 and ESMO's congress platform blocks automated access, so ESMO abstracts here come from web research: each row was found on a published congress report and verified against it.
- LBA14Late-breakingA double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/FINER studyAndrew D. RedfernCCTG/BCT MA.40/FINERfulvestrantipatasertibMatches source excerptcslide.ctimeetingtech.com
- LBA15Late-breakingAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III studyBinghe Xuanbenitamabalbumin-bound docetaxelMatches source excerptcslide.ctimeetingtech.com
- LBA16Late-breakingVIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)Barbara PistilliVIKTORIA-1gedatolisibfulvestrantpalbociclibMatches source excerptcslide.ctimeetingtech.com
- LBA17Late-breakingHER2-PET imaging to predict trastuzumab deruxtecan (T-DXd) efficacy in advanced breast cancer: The phase II PREDICT-HER trialJuan JinPREDICT-HERtrastuzumab deruxtecan (T-DXd)Matches source excerptcslide.ctimeetingtech.com
- LBA23Late-breaking
- LBA24Late-breakingFinal analysis of NRG oncology/NSABP B-42, a randomized, double-blinded, placebo-controlled trial of extended letrozole in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitorMatches source excerptcslide.ctimeetingtech.com
- LBA25Late-breaking
- LBA26Late-breakingShort-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trialJoana M. RibeiroUNLOCK 14 - POP-DURVAdurvalumabMatches source excerptcslide.ctimeetingtech.com
- LBA27Late-breaking
- LBA28Late-breaking
- LBA49Late-breakingA DESTINY-Breast09 (DB-)09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs)Cristina Saura ManichDESTINY-Breast09trastuzumab deruxtecan (T-DXd)pertuzumabtaxanetrastuzumabMatches source excerptcslide.ctimeetingtech.com
- LBA50Late-breakingPANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)Bo LanPANKU-Breast01izalontamab brengitecan (iza-bren)Matches source excerptcslide.ctimeetingtech.com
- LBA51Late-breaking
- LBA96Late-breakingFirst-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts with brain metastases in TROPION-Breast02Rebecca A. DentTROPION-Breast02NCT05374512datopotamab deruxtecan (Dato-DXd)nab-paclitaxelcapecitabineeribulin mesylateMatches source excerptcslide.ctimeetingtech.com
- 1842OOral presentationEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)Antonio GiordanoFOURLIGHT-1atirmociclib (ATI)fulvestrant (FUL)Matches source excerptcslide.ctimeetingtech.com
- 1RORapid oralOverall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapyKevin KalinskypostMONARCHabemaciclibfulvestrantMatches source excerptcslide.ctimeetingtech.com
- 2RORapid oralRetrospective exploratory biomarker (BM) analyses from evERA breast cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) settingMatches source excerptcslide.ctimeetingtech.com
- 3RORapid oral
- 4RORapid oral
- 5RORapid oralSafety and efficacy of SYS6043, a novel B7-H3—targeting antibody-drug conjugate, in patients with advanced breast cancerHongxia WangSYS6043Matches source excerptcslide.ctimeetingtech.com
- 538RORapid oralPatient (pt)-reported outcomes (PROs) from the Phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC)Gustavo WerutskylidERAgiredestrant (GIRE)Matches source excerptcslide.ctimeetingtech.com
- 539RORapid oralPatient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)Carlos H. BarriosDESTINY-Breast05trastuzumab deruxtecan (T-DXd)trastuzumab emtansine (T-DM1)Matches source excerptcslide.ctimeetingtech.com
- 540RORapid oral
- 542RORapid oralPrognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1Yukinori OzakiJCOG1204A1Matches source excerptcslide.ctimeetingtech.com
- 543RORapid oralDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in HER2+ early breast cancer (eBC)Jean-Francois BoileauDESTINY-Breast11NCT05113251trastuzumab deruxtecan (T-DXd)paclitaxeltrastuzumabpertuzumabMatches source excerptcslide.ctimeetingtech.com
- 544RORapid oralFinal analysis of the GIM3 FATA trial: Treatment schedule and three aromatase inhibitors (AIs) comparison in postmenopausal HR-positive (HR+) early breast cancer (eBC)Pietro De PlacidoGIM3 FATAanastrozoleexemestaneletrozoletamoxifenMatches source excerptcslide.ctimeetingtech.com
- 545RORapid oral
- 1766RORapid oralHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBCVeronique C. DierasHER2CLIMB-05tucatinibtrastuzumabpertuzumabMatches source excerptcslide.ctimeetingtech.com
- 1767RORapid oral
- 1768RORapid oralRadiation therapy followed by intrathecal (IT) trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal metastasis: Results from a phase II multi-institutional study, (INSPIRE-LM)Kamran AhmedINSPIRE-LMtrastuzumabpertuzumabMatches source excerptcslide.ctimeetingtech.com
- 1769RORapid oralCTC characterization with the DETECT CTC score predicts therapy response in triple-positive aBC: Translational results of the phase III DETECT V studyKerstin PfisterDETECT VMatches source excerptcslide.ctimeetingtech.com
- 4639RORapid oralFinal OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01Ying Fan (presented by Man Li)OptiTROP-Breast01sacituzumab tirumotecanMatches source excerptcslide.ctimeetingtech.com
- 4640RORapid oralBulumtatug fuvedotin (BFv, 9MW2821), a nectin-4–directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic triple negative breast cancer (la/mTNBC) previously treated with topoisomerase I inhibitor (TopI)-based ADCs: Results from a phase 2 studyMatches source excerptcslide.ctimeetingtech.com
- LBA29Late-breaking
- LBA30Late-breaking
- LBA31Late-breakingBiweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trialHiroya TaniguchiPRABITAStrifluridine/tipiracilbevacizumabMatches source excerptcslide.ctimeetingtech.com
- LBA32Late-breaking
- LBA87Late-breaking
- 3530OOral presentation
- 787RORapid oralCirculating tumor DNA (ctDNA)-guided re-treatment (re-tx) with encorafenib and cetuximab (EC) in patients (pts) with chemorefractory BRAFV600E mutated metastatic colorectal cancer (mCRC): The proof-of-concept single arm phase II BRICKET trial by GONOVittorio Studiale (presented by Marco Maria Germani)BRICKETencorafenibcetuximabMatches source excerptcslide.ctimeetingtech.com
- 788RORapid oral
- 789RORapid oralTRIDENTE: A phase II study of rechallenge with encorafenib (ENCO), binimetinib (BINI), and cetuximab (CET) in BRAF V600E-mutant metastatic colorectal cancer (mCRC)Daisuke KotaniTRIDENTEencorafenibbinimetinibcetuximabMatches source excerptcslide.ctimeetingtech.com
- 790RORapid oral
- 791RORapid oralLong-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 studyMichael CecchiniNCT05029882telisotuzumab adizutecan (ABBV-400, Temab-A)bevacizumabtrifluridine/tipiracil (TAS-102)Matches source excerptcslide.ctimeetingtech.com
- 692OOral presentation
- 693OOral presentation
- 694OOral presentation
- 695RORapid oral
- 121PPosterMRI radiomics-guided drug reversal analysis for therapeutic vulnerability mapping in glioblastomaYuzuha KadookaMatches source excerptcslide.ctimeetingtech.com
- 704PPoster
- 706PPosterIvonescimab combined with dose-dense temozolomide in recurrent glioblastoma: Preliminary results of efficacy and safety from a single-arm, phase Ib/II trialLi YanchuivonescimabtemozolomideMatches source excerptcslide.ctimeetingtech.com
- 707PPosterTeniposide plus cisplatin or carboplatin in recurrent high-grade glioma: Pre-planned interim analysis of an ongoing multicenter, open-label, single-arm trialBohao Zhang (presented by Wenbin Li)teniposidecisplatincarboplatinMatches source excerptcslide.ctimeetingtech.com
- 709PPosterEarly metabolic response and seizure control with vorasidenib in IDH-mutant gliomas: Real-world results from the VORAFET studyVORAFETvorasidenibMatches source excerptcslide.ctimeetingtech.com
- 710PPoster
- 712PPoster
- 713PPoster
- 714PPoster
- 716PPoster[68Ga]Ga-anti-integrin peptide for imaging αvβ3 in glioblastomaJuliana Carron (presented by Carmen S. Passos Lima)[68Ga]Ga-anti-integrin peptideMatches source excerptcslide.ctimeetingtech.com
- 717PPosterPrognostic and therapeutic implications of routine NGS in IDHwt high-grade gliomasMathieu LarroquetteMatches source excerptcslide.ctimeetingtech.com
- 718ePPoster
- 727TiPPoster
- 730ePPoster
- 739ePPosterReal-world efficacy and safety of vorasidenib in IDH-mutant grade 2 gliomas: A multicenter study from SpainvorasidenibMatches source excerptcslide.ctimeetingtech.com
- 765ePPosterDiagnostic and treatment pathway experience in primary brain tumours: A cross-sectional analysisJuan Manuel Sepulveda SanchezMatches source excerptcslide.ctimeetingtech.com
- 771ePPosterCDKN2A-altered gliomas: Real-world outcomes across subtypes from the RETSINE/GEINO registryEstela Pineda (presented by Sonia Del Barco)temozolomidebevacizumabMatches source excerptcslide.ctimeetingtech.com
- LBA5Presidential
- LBA6Presidential
- LBA62Late-breaking
- LBA64Late-breakingToripalimab plus chemotherapy as perioperative treatment for resectable stage II or III non-small cell lung cancer (NSCLC): Final analysis of the Phase 3 Neotorch studyShun LuNeotorchtoripalimabchemotherapyVerified on a second sourceliangyihui.net
- LBA65Late-breaking
- LBA66Late-breakingSacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 studyCaicun ZhouOptiTROP-Lung06sacituzumab tirumotecanpembrolizumabchemotherapyVerified on a second sourceliangyihui.net
- LBA67Late-breakingFinal OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 studyLi ZhangOptiTROP-Lung04sacituzumab tirumotecanplatinum-based chemotherapyVerified on a second sourceliangyihui.net
- LBA68Late-breakingPhase 3 study of sigvotatug vedotin (SV) vs docetaxel (DTX) in previously treated nonsquamous non-small cell lung cancer (NSCLC)Solange Peterssigvotatug vedotindocetaxelVerified on a second sourceliangyihui.net
- LBA69Late-breaking
- LBA71Late-breakingPANKU-Lung01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in EGFR-Mutant Non-squamous Non‑Small Cell Lung Cancer (NSCLC) After Progression on a Third Generation EGFR TKILi ZhangPANKU-Lung01izalontamab brengitecanVerified on a second sourceliangyihui.net
- LBA72Late-breakingRuzaltatug rezetecan, a HER3-directed ADC, vs platinum-based chemotherapy (PBC) in EGFR-mutated advanced NSCLC progressing after EGFR-TKI: interim analyses (IA) from the phase 3 HERON-Lung01 trialYi-Long WuHERON-Lung01ruzaltatug rezetecanplatinum-based chemotherapyVerified on a second sourceliangyihui.net
- LBA73Late-breakingPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line treatment (AIO-TRK-0422/ass)Martin SebastianPACE-LUNGosimertinibchemotherapyVerified on a second sourcecslide.ctimeetingtech.com
- LBA74Late-breakingFirst-line (1L) trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) NSCLC: patient-reported outcomes (PROs) from DESTINY-Lung04 (DL-04)DESTINY-Lung04 (DL-04)trastuzumab deruxtecanVerified on a second sourceliangyihui.net
- LBA75Late-breakingDeulorlatinib (TGRX‑326) vs crizotinib in TKI-naive advanced ALK+ NSCLC: a phase 3 studydeulorlatinibcrizotinibVerified on a second sourceliangyihui.net
- LBA76Late-breakingA global phase 2, open-label trial of pumitamig (PD-L1 × VEGF-A bsAb) + docetaxel post-chemoimmunotherapy in mNSCLC: first data from ROSETTA Lung-107ROSETTA Lung-107pumitamigdocetaxelMatches source excerptliangyihui.net
- 2511OOral presentationFinal analysis of adjuvant pembrolizumab (pembro) in resected early-stage non–small-cell lung cancer (NSCLC): Phase 3 PEARLS/KEYNOTE-091 studyPEARLS/KEYNOTE-091pembrolizumabVerified on source pageoncoletter.ch
- 2519OOral presentationAssociation of biomarkers with efficacy in the phase 3 KEYNOTE-671 study of perioperative pembrolizumab (Pembro) plus neoadjuvant chemotherapy (Chemo) in early-stage non–small-cell lung cancer (NSCLC)KEYNOTE-671pembrolizumabchemotherapyVerified on source pageoncoletter.ch
- 2613OOral presentation
- 2614OOral presentationPembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC with PD-L1 ≥50%: PERSEE phase 3 trial (GFPC 01-2020)PERSEE (GFPC 01-2020)pembrolizumabplatinum-based chemotherapyVerified on source pageoncoletter.ch
- 1950RORapid oral
- 2615RORapid oralDalmelitinib plus Aumolertinib versus platinum-based chemotherapy in advanced NSCLC patients with MET amplification post EGFR TKI: a randomized, phase 3 studydalmelitinibaumolertinibplatinum-based chemotherapyVerified on source pageioncology.com.cn
- 2616RORapid oral
- 2617RORapid oral
- 2618RORapid oralAnalysis of the phase 2 part of IFCT-2103 DIAL phase 2-3 randomized trial, comparing continuation pembrolizumab (± pemetrexed) up to 2 years versus observation (± pemetrexed), in patients with metastatic Non-Small Cell Lung Cancer (mNSCLC) with disease control (DC) at 6 monthsIFCT-2103 DIALpembrolizumabpemetrexedVerified on source pageioncology.com.cn
- 2631RORapid oralFirst-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 studyBAT8008BAT1308Verified on source pageoncoletter.ch
- 2636RORapid oral
- 2646RORapid oralA phase 2 trial of JS207 (PD-1/VEGF bispecific antibody) plus chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC)JS207chemotherapyVerified on source pageioncol.com
- 2658RORapid oralOverall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human studytelisotuzumab adizutecanVerified on source pageoncoletter.ch
- 2700RORapid oral
- 2719RORapid oralFLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)FLAURA2osimertinibplatinum–pemetrexedVerified on source pageoncoletter.ch
- 4247RORapid oralImmunogenomic signature associated with ICI-related pneumonitis in non-small cell lung cancer (NSCLC) patientsJarushka NaidooVerified on a second sourcecslide.ctimeetingtech.com
- 209PPosterAI-driven quantification of PD-L1 tumor proportion score (TPS) from immunohistochemistry slides in non-small cell lung cancer (NSCLC)Ana D. Ramos GuerraMatches source excerptcslide.ctimeetingtech.com
- 358PPosterMultimodal [18F]FDG-PET/CT foundation model framework for 24-month overall survival prediction in immunotherapy-treated advanced NSCLCBeshoy Guirges (presented by Rebecca Romanò)Matches source excerptcslide.ctimeetingtech.com
- 2515PPoster
- 2528PPosterReal-world outcomes of neoadjuvant and perioperative chemoimmunotherapy in resectable NSCLC: First analysis from “NeoReal study”Federica BertoliniNeoReal studynivolumabdurvalumabpembrolizumabMatches source excerptcslide.ctimeetingtech.com
- 2535PPoster
- 2536PPoster
- 2539PPosterClinical outcomes and recurrence patterns in early-stage fusion-positive NSCLC treated with initial surgery or SBRT: A retrospective institutional analysisAlexander Drilon (presented by Jaime Rubio Perez)Matches source excerptcslide.ctimeetingtech.com
- 2540PPoster
- 2543PPosterImpact of STAS and type of surgical resection in stage I lung adenocarcinomaMaria Alameda-GuijarroMatches source excerptcslide.ctimeetingtech.com
- 2546PPosterPreferences for adjuvant immunotherapy (AIT) after resection of NSCLC in BR.31: What survival benefits would make it worthwhile to participants (pts)?Kristin WrightBR.31durvalumabplaceboMatches source excerptcslide.ctimeetingtech.com
- 2547PPoster
- 2548PPoster
- 2573PPosterImneskibart (AU-007) + low-dose SC IL-2 + avelumab: Phase 2 activity in CPI-refractory advanced adenocarcinoma NSCLCimneskibart (AU-007)low-dose SC IL-2avelumabVerified on source pageaulosbio.com
- 2577PPoster
- 2583PPoster
- 2588PPosterMulticentre real-world analysis of predictors of survival after neoadjuvant immunochemotherapy in locally resectable non-small cell lung cancer (KOMPASS neo OP)Martin FaehlingKOMPASS neo OPMatches source excerptcslide.ctimeetingtech.com
- 2592PPosterDynamic cytokine profiling suggests an association between IP-10 and progression-free survival in locally advanced NSCLC treated with durvalumab after chemoradiotherapySaima J. FarooqiDARTdurvalumabMatches source excerptcslide.ctimeetingtech.com
- 2627PPoster
- 2636PPoster
- 2656PPoster
- 2660PPoster
- 2669PPoster
- 2676PPosterUpdated real-world outcomes with first-line lorlatinib in ALK-positive advanced NSCLC in Japan: ROYAL study second interim analysisROYALlorlatinibVerified on source pagecdn.pfizer.com
- 2688PPoster
- 2694PPoster
- 2696PPosterMolecular profile, treatment patterns, and real-world outcomes in HER2-mutant NSCLC: Results from the AACR project GENIE registryKenneth Kehl (presented by Brian Piening)Matches source excerptcslide.ctimeetingtech.com
- 2697PPoster
- 2702PPosterRET fusion–positive non-small cell lung cancer (NSCLC): Real-world data from the Italian ATLAS registryMaria Lucia RealeMatches source excerptcslide.ctimeetingtech.com
- 2711PPosterIntracranial progression-free survival with ivonescimab-based therapy in advanced NSCLC with baseline brain metastasesDaniel T. JonesHARMONi-A; HARMONi-2; HARMONi-6ivonescimabMatches source excerptcslide.ctimeetingtech.com
- 4161PPoster
- 4421PPosterSystemic inflammation and IL-1 signalling in EGFR-mutated non-small cell lung cancer treated with first-line osimertinibAndrea De Giglio (presented by Alessandro Di Federico)osimertinibMatches source excerptcslide.ctimeetingtech.com
- LBA82Late-breaking
- LBA83Late-breakingSeven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma (PDAC): The AMPLIFY-7P randomized phase 2 studyEileen M. O'ReillyAMPLIFY-7PELI-002 7PMatches source excerptcslide.ctimeetingtech.com
- LBA33Mini oral
- LBA85Mini oral
- 3136ROMini oralRandomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trialAGITG MASTERPLANmFOLFIRINOXgemcitabinenab-paclitaxelMatches source excerptcslide.ctimeetingtech.com
- 3137ROMini oral
- 3896ROMini oral
- 3150PPoster
- 3160PPoster
- 3162PPoster
- 3166PPoster
- 3178PPoster
- 3180PPosterUnveiling early-onset pancreatic cancer: Clinical, molecular and therapeutic insights from a real-world cohortAina De Torner VidalMatches source excerptcslide.ctimeetingtech.com
- 3184PPosterSafety and efficacy of PBP1510, an Anti-PAUF monoclonal antibody, in metastatic pancreatic adenocarcinomaDaniel A. KingPAUF-IPBP1510gemcitabineMatches source excerptcslide.ctimeetingtech.com
- 3190TiPPoster
- 3258ePPosterMultidimensional analysis of recurrence after curative-intent resection of pancreatic ductal adenocarcinomaSergio Perez-FernandezMatches source excerptcslide.ctimeetingtech.com
- 4303PPoster
Paediatric cancers
1 verified · pulled 2026-11-11- 4457PPoster